Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group

The New England Journal of Medicine
D HoskingA J Yates

Abstract

Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear. We studied the effect of 2.5 mg or 5 mg of alendronate per day or placebo on bone mineral density in 1174 postmenopausal women under 60 years of age. An additional 435 women who were prepared to receive a combination of estrogen and progestin were randomly assigned to one of the above treatments or open-label estrogen-progestin. The main outcome measure was the change in bone mineral density of the lumbar spine, hip, distal forearm, and total body measured annually for two years by dual-energy x-ray absorptiometry. The women who received placebo lost bone mineral density at all measured sites, whereas the women treated with 5 mg of alendronate daily had a mean (+/-SE) increase in bone mineral density of 3.5+/-0.2 percent at the lumbar spine, 1.9+/-0.1 percent at the hip, and 0.7+/-0.1 percent for the total body (all P<0.001). Women treated with 2.5 mg of alendronate daily had smaller increases in bone mineral density. Alendronate did not increase bone min...Continue Reading

Associated Clinical Trials

References

Sep 24, 1977·British Medical Journal·A HorsmanB E Nordin
Jun 1, 1992·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·D M BlackL J Melton
Apr 1, 1992·British Medical Bulletin·E DalyM Vessey
Aug 27, 1992·The New England Journal of Medicine·B L Riggs, L J Melton
Jul 12, 1990·The New England Journal of Medicine·N B WattsM J Yanover
Feb 1, 1986·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·D W DempsterR Lindsay
Aug 1, 1980·European Journal of Clinical Investigation·C ChristiansenI Transbøl
Jun 15, 1995·The New England Journal of Medicine·G A ColditzF E Speizer
Jan 1, 1993·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·G A RodanR Balena
May 1, 1993·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·L J MeltonB L Riggs
Feb 1, 1996·Obstetrics and Gynecology·R Lindsay
Feb 1, 1996·Obstetrics and Gynecology·R A Wild
Aug 15, 1996·The New England Journal of Medicine·F GrodsteinC H Hennekens
Oct 3, 1996·The New England Journal of Medicine·P C de GroenK K Wang

❮ Previous
Next ❯

Citations

Jan 18, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Robert LindsayJames H Pickar
May 11, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M VisW F Lems
Oct 6, 2009·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·T V Nguyen
Jun 11, 2010·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·L XuG D Constantine
Oct 27, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J Yates
Apr 19, 2013·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J-M KaufmanA Chines
Jul 30, 2009·Wiener medizinische Wochenschrift. Supplement·Hans Peter DimaiUNKNOWN Austrian Society for Bone and Mineral Research (AuSBMR)
Nov 6, 2010·Current Oncology Reports·Allan Lipton
Mar 5, 2004·Surgical Oncology·J M Dixon
Oct 26, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·J J Stĕpán, J Vokrouhlická
Nov 6, 1998·Disease-a-month : DM·W B Cutler, E Genovese-Stone
Sep 30, 2003·The Journal of Allergy and Clinical Immunology·David B AllenStanley J Szefler
Jun 22, 2002·Lancet·Pierre D Delmas
Dec 10, 2002·Cancer Treatment Reviews·Mark ClemonsBeverley Anderson
Jun 8, 2001·Maturitas·C Christiansen
Jan 9, 1999·Maturitas·C Netelenbos
Jul 17, 1999·Trends in Endocrinology and Metabolism : TEM·J P BilezikianC J Rosen
Feb 7, 2001·Trends in Endocrinology and Metabolism : TEM·L V Avioli
Mar 10, 2001·Clinics in Liver Disease·S J MunozC Manzarbeitia
Feb 24, 2001·Joint, Bone, Spine : Revue Du Rhumatisme·C Marcelli
Nov 15, 2001·Joint, Bone, Spine : Revue Du Rhumatisme·J M PouillesF Trémollières
Feb 18, 2003·Journal of Midwifery & Women's Health·Michele R Davidson
May 16, 2003·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·F Lanza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.